Episode 252: Talazoparib and Its FDA Approval in CRPC

By The Uromigos - Last Updated: July 6, 2023

Neeraj Agarwal, MD, joins us to discuss the TALAPRO-2 study and the relevance of homologous recombination repair biomarkers in the study’s 2 cohorts. We also discuss other PARP inhibitors and BRCA 1/2 occurrences.
Dr. Agarwal is a professor of medicine and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah. He is also director of the institute’s Genitourinary Oncology Program, and the Center of Investigational Therapeutics.

Post Tags:Uromigos-Prostate Cancer